Memo Therapeutics has raised CHF14 million ($15.56 million) in a Series B financing round towards the clinical development of potent antibodies for the immunotherapy of Covid-19. The proceeds from the funding round will also help the Swiss biotech company in developing antibodies for BK virus infection in kidney transplant patients. The funding round was led […]
Memo Therapeutics (MTx), a Swiss biotech company, has entered into a partnership with Northway Biotechpharma, under which the latter will manufacture the former’s MTX-COVAB – a COVID-19 antibody candidate in a four-month fast-track process. Northway Biotechpharma is a biopharmaceutical contract development and manufacturing organization (CDMO) based in Lithuania. MTX-COVAB, which is the lead antibody candidate […]
